Bausch Health Companies Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Bausch Health Companies Inc(Bausch Health) formerly known as Valeant Pharmaceuticals International Inc, develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Bausch Health offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Bausch Health is headquartered in Laval, Quebec, Canada.

Bausch Health Companies Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 7
List of Figures 9
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bausch Health Companies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Bausch Health Companies Inc, Medical Devices Deals, 2012 to YTD 2018 15
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deal Details 23
Asset Purchase 23
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 23
Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 24
Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 26
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 27
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 28
Valeant Pharma Acquires Pharma Brands from Probiotec 29
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 31
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 32
Valeant Pharma Acquires US Rights To Targretin From Eisai 33
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 34
Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 35
Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 36
Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 37
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 38
Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 39
Venture Financing 40
Precision Dermatology Raises Additional US$26 Million In Venture Financing 40
Private Equity 41
Pacific Equity and Carlyle Acquires iNova Pharma from Valeant Pharma for USD930 Million 41
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 43
Partnerships 44
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 44
Namtall Enters into Licensing Agreement with Valeant Pharma 46
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 47
Dova Pharma and Valeant Pharma Enter into Co-Promotion Agreement 48
Salix Pharma Enters into Research Agreement with Cedars-Sinai Medical Center 49
US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 50
Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 51
Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 52
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 53
Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 54
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 55
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 56
Lupin Enters into Distribution Agreement with Salix Pharma 57
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 58
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 59
Valeant Pharmaceuticals International Partners With Living Proof 60
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 61
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 62
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 63
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 64
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 65
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 66
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 67
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 68
Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 69
Licensing Agreements 70
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 70
Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 71
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 72
Valeant Pharma Amends Licensing Agreement with AstraZeneca 73
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 74
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 75
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 76
Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 77
Sirona Biochem Expands Licensing Agreement with Valeant Pharma 78
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 79
Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC-849 80
Valeant Pharma Enters into Licensing Agreement with SMG Pharma 81
Ono Pharma Enters into Licensing Agreement with Valeant Pharma 82
Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 83
Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 84
Valeant Pharma Enters into Licensing Agreement with Norgine 85
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 86
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 87
Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 88
Equity Offering 89
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 89
Atlantic Healthcare Raises USD24 million in Private Placement of Shares 90
Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 91
Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 93
Bausch & Lomb Withdraws IPO 95
Debt Offering 97
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 97
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 98
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 99
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 100
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 101
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 102
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 103
Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due 2023 104
Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due 2023 105
Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due 2020 106
Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due 2025 107
Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due 2023 108
Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds 109
Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 110
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 111
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 112
Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 113
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 114
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 115
Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 116
Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 118
Asset Transactions 120
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 120
Valeant Pharma Receives Unsolicited Bids for its Core Assets 122
Valeant Pharma May Sell its Dermatology and Cancer Drugs 123
Valeant Pharma Plans to Sell Neuro Business 124
IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 125
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 126
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 127
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 128
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 130
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 131
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 132
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 133
Acquisition 134
Valeant Pharma Sells Sprout Pharma 134
Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 135
Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 136
Pershing Square Capital Management Sells its Investment in Valeant Pharma 138
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 139
Valeant Pharma May Sell Amoun Pharma 140
Valeant Pharma to Acquire Mercury (Cayman) 141
Valeant Pharma Acquires Sprout Pharma 143
Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 145
Valeant Pharma Acquires Nicox for USD20 Million 148
Valeant Canada Acquires CROMA Pharma Canada 149
Valeant Pharma Completes Acquisition of PreCision Dermatology 150
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 152
Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 153
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 155
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 157
Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 158
Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 160
Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 161
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 162
Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 164
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 166
Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 167
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 168
Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 170
Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 172
Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 173
Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 174
Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 175
Bausch Health Companies Inc - Key Competitors 176
Bausch Health Companies Inc - Key Employees 177
Bausch Health Companies Inc - Locations And Subsidiaries 178
Head Office 178
Other Locations & Subsidiaries 178
Recent Developments 187
Financial Announcements 187
May 08, 2018: Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance 187
Feb 28, 2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results 190
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 194
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 196
May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 199
Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 200
Corporate Communications 204
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 204
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 205
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 206
Legal and Regulatory 207
Sep 28, 2018: Salix Resolves Legacy SEC Investigation With No Penalty 207
May 15, 2018: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors 208
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 209
Other Significant Developments 210
Sep 27, 2018: Bausch Health Releases First Annual Corporate Social Responsibility Report 210
May 08, 2018: Valeant Will Become Bausch Health Companies 211
Feb 27, 2017: Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity 212
Appendix 213
Methodology 213
About GlobalData 213
Contact Us 213
Disclaimer 213

List Of Tables


Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bausch Health Companies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bausch Health Companies Inc, Deals By Therapy Area, 2012 to YTD 2018 13
Bausch Health Companies Inc, Medical Devices Deals, 2012 to YTD 2018 15
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 23
Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 24
Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 26
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 27
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 28
Valeant Pharma Acquires Pharma Brands from Probiotec 29
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 31
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 32
Valeant Pharma Acquires US Rights To Targretin From Eisai 33
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 34
Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 35
Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 36
Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 37
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 38
Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 39
Precision Dermatology Raises Additional US$26 Million In Venture Financing 40
Pacific Equity and Carlyle Acquires iNova Pharma from Valeant Pharma for USD930 Million 41
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 43
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 44
Namtall Enters into Licensing Agreement with Valeant Pharma 46
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 47
Dova Pharma and Valeant Pharma Enter into Co-Promotion Agreement 48
Salix Pharma Enters into Research Agreement with Cedars-Sinai Medical Center 49
US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 50
Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 51
Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 52
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 53
Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 54
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 55
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 56
Lupin Enters into Distribution Agreement with Salix Pharma 57
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 58
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 59
Valeant Pharmaceuticals International Partners With Living Proof 60
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 61
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 62
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 63
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 64
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 65
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 66
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 67
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 68
Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 69
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 70
Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 71
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 72
Valeant Pharma Amends Licensing Agreement with AstraZeneca 73
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 74
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 75
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 76
Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 77
Sirona Biochem Expands Licensing Agreement with Valeant Pharma 78
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 79
Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC-849 80
Valeant Pharma Enters into Licensing Agreement with SMG Pharma 81
Ono Pharma Enters into Licensing Agreement with Valeant Pharma 82
Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 83
Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 84
Valeant Pharma Enters into Licensing Agreement with Norgine 85
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 86
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 87
Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 88
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 89
Atlantic Healthcare Raises USD24 million in Private Placement of Shares 90
Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 91
Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 93
Bausch & Lomb Withdraws IPO 95
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 97
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 98
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 99
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 100
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 101
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 102
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 103
Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due 2023 104
Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due 2023 105
Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due 2020 106
Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due 2025 107
Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due 2023 108
Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds 109
Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 110
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 111
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 112
Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 113
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 114
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 115
Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 116
Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 118
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 120
Valeant Pharma Receives Unsolicited Bids for its Core Assets 122
Valeant Pharma May Sell its Dermatology and Cancer Drugs 123
Valeant Pharma Plans to Sell Neuro Business 124
IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 125
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 126
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 127
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 128
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 130
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 131
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 132
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 133
Valeant Pharma Sells Sprout Pharma 134
Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 135
Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 136
Pershing Square Capital Management Sells its Investment in Valeant Pharma 138
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 139
Valeant Pharma May Sell Amoun Pharma 140
Valeant Pharma to Acquire Mercury (Cayman) 141
Valeant Pharma Acquires Sprout Pharma 143
Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 145
Valeant Pharma Acquires Nicox for USD20 Million 148
Valeant Canada Acquires CROMA Pharma Canada 149
Valeant Pharma Completes Acquisition of PreCision Dermatology 150
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 152
Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 153
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 155
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 157
Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 158
Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 160
Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 161
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 162
Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 164
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 166
Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 167
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 168
Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 170
Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 172
Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 173
Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 174
Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 175
Bausch Health Companies Inc, Key Competitors 176
Bausch Health Companies Inc, Key Employees 177
Bausch Health Companies Inc, Other Locations 178
Bausch Health Companies Inc, Subsidiaries 178

List Of Figures


Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bausch Health Companies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Bausch Health Companies Inc, Medical Devices Deals, 2012 to YTD 2018 15

Bausch Health Companies Inc (BHC) - Financial and Strategic SWOT Analysis Review

Bausch Health Companies Inc (BHC) - Financial and Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 125

USD 125 View Report

Bausch Health Companies Inc (VRX) - Medical Equipment - Deals and Alliances Profile

Bausch Health Companies Inc(Bausch Health) formerly known as Valeant Pharmaceuticals International Inc, develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such

USD 250 View Report

Bausch Health Companies Inc (BHC) - Financial and Strategic SWOT Analysis Review

Bausch Health Companies Inc (BHC) - Financial and Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 125

USD 125 View Report

Leading Animal Health Companies: Marketing Tactics, Technological Know-How and Global Sales Segment Forecasts, 2019-2023

This new report provides global animal health market outlook and leading suppliers' strategies, marketing tactics, and technological know-how. The report presents a worldwide strategic overview of the animal health market,

USD 3450 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available